1.C.110.1.1 The PNC-37 (32 aas) pore-forming peptide derived from the Mdm-2 binding domain of the p53 tumor-supressor protein which is selectively cytotoxic to cancer cells. The 3-d structure is known from NMR analyses (Sookraj et al. 2010). PNC-37 binds to HDM-2 in a 1:1 stoichiometry to induce pore-formation, and the pores are lined by PNC-37 bound to HDM-2 at the membrane surface with
the PNC-37 leader sequence lining the pores (Sarafraz-Yazdi et al. 2022). The interaction of the C-terminal domain of Vaccinia-Related Kinase 2A (VRK2A) with the B-cell lymphoma-extra Large (Bcl-xL) plays an anti-apoptotic role in cancer (Puja et al. 2023). P53 is a multifunctional protein implicated in the regulation of diverse
cellular processes via transcription-dependent and
transcription-independent mechanisms (Wang et al. 2024). Mitochondria maintain cellular function, and mitochondrial
defects or impairment are primary causes of dopaminergic neuron
degeneration in PD. Mitochondrial
dysfunction-associated dopaminergic neuron degeneration is tightly
regulated by p53 in PD pathogenesis. Neurodegenerative stress triggers
p53 activation, which induces mitochondrial changes, including
transmembrane permeability, reactive oxygen species production, Ca2+ overload, electron transport chain defects and other dynamic
alterations, and these changes contribute to neurodegeneration and are
linked closely with PD occurrence and development. P53 inhibition has
been shown to attenuate mitochondrial dysfunction and protect
dopaminergic neurons from degeneration under conditions of
neurodegenerative stress (Wang et al. 2024).
|
Accession Number: | P04637 |
Protein Name: | Cellular tumor antigen p53 |
Length: | 393 |
Molecular Weight: | 43653.00 |
Species: | Homo sapiens (Human) [9606] |
Location1 / Topology2 / Orientation3: |
Cytoplasm1 |
Substrate |
molecule |
---|
1: MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
61: DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
121: SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
181: RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
241: SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
301: PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
361: GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD